<DOC>
	<DOCNO>NCT00794235</DOCNO>
	<brief_summary>Investigation metabolic activity sorafenib sorafenib plus dacarbazine melanoma metastasis patient melanoma stage III IV basis PET/CT , LDH S-100 evaluation . As hypothezise direct influence transcriptome drug via antiproliferative apoptotic signal , biopsy melanoma skin metastasis assess microarrays direct change reveal . If positive effect transcriptional profile metastasis reveal , patient metastatic melanoma would benefit drug result tumor regression . Therefore , total 12 patient skin- superficial lymph node metastasis diameter least 1 cm choose sorafenib therapy 56 day per os twice daily 400 mg , additionally , day 14 42 , intravenous dacarbazine infusion ( volume depend body surface area ( 1000 mg/m2 ) ) . Before treatment sorafenib , treatment dacarbazine , treatment , S100 LDH measure serum , PET/CT conduct biopsy take one skin metastasis day .</brief_summary>
	<brief_title>Monocentric Pilot Study Investigating Metabolic Activity Melanoma Vivo During Sorafenib Dacarbazine</brief_title>
	<detailed_description>A total 12 patient skin- superficial lymph node metastasis diameter least 1 cm choose sorafenib therapy 56 day per os twice daily 400 mg , additionally , day 14 42 , intravenous dacarbazine infusion ( volume depend body surface area ( 1000 mg/m2 ) ) . On screen day , medical history well physical examination determine vital sign analyze coagulation status venous blood conduct . In woman , pregnancy test conduct . On screen day , well day 10 , 16 , 35 60 , venous blood take examination hematology ( hemoglobin , hematocrit , red blood cell ( RBC ) count , platelet , white blood cell ( WBC ) count differential ( total neutrophil , lymphocyte , monocyte , eosinophil basophil ) , biochemistry ( sodium , potassium , urea , creatinine , phosphate , glucose , alanine aminotransferase ( ALT ) , gGT , alkaline phosphatase , total bilirubin , albumin , total lipid status LDL-cholesterol , HDL-cholesterol , triglyceride ) , S-100 , LDH , asservation 40 ml EDTA 10 ml Serum . At every consultation ( screen day , day 1 , 10 , 14 , 16 , 35 , 42 , 60 ) , concomitant medication record , vital sign determine . At every consultation except screen day day 1 , adverse event report . FDG-PET/CT conduct screen day , day 10 , 16 60 ; afterward , one cutaneous metastasis include previous PET/CT scan , biopsied investigate gene processing profile ( day 60 optional ) .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Age &gt; 18 year . 2 . Histologically cytologically confirm unresectable ( stage III ) metastatic ( stage IV ) melanoma treatment dacarbazine consider medically acceptable . 3 . No prior chemotherapy . 4 . ECOG Performance Status 0 1 . 5 . Life expectancy least 12 week . 6 . Subjects least one unidimensional ( RECIST ) bidimensional ( WHO ) measurable lesion . Lesions must measure CTscan MRI . 7 . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior screen : Hemoglobin &gt; = 9.0 g/dl . Absolute neutrophil count ( ANC ) &gt; =1,500/mm3 . Platelet count &gt; =100,000/Ã¬l . Total bilirubin &lt; = 1.5 time upper limit normal . ALT AST &lt; = 2.5 x upper limit normal ( &lt; 5 x upper limit normal patient liver involvement cancer ) . Alkaline phosphatase &lt; 4 x ULN . PTINR/PTT &lt; 1.5 x upper limit normal [ Patients therapeutically anticoagulated agent coumadin heparin allow participate provide prior evidence underlie abnormality parameter exist ] . Serum creatinine &lt; = 1.5 x upper limit normal . 8 . Signed date informed consent start specific protocol procedure . 9 . Baseline serum LDH level &gt; 1.1 ULN . 10 . Assessable metastasis ( Skin superficial lymph node , minimal diameter 1 cm ) EXCLUSION CRITERIA : 1 . History cardiac disease : congestive heart failure &gt; NYHA class 2. active CAD ( MI 6 month prior study entry allow ) ; cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension . 3 . History HIV infection chronic hepatitis B C. 4 . Active clinically serious infection ( &gt; grade 2 NCICTC version 3.0 ) . 5 . Symptomatic metastatic brain meningeal tumor ( unless patient &gt; 6 month definitive therapy , negative imaging study within 4 week study entry clinically stable respect tumor time study entry ) . 6 . Patients seizure disorder require medication ( steroids antiepileptic ) . 7 . History organ allograft . 8 . Patients evidence history bleed diathesis . 9 . Patients undergoing renal dialysis . 10 . Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis &amp; T1 ] cancer curatively treat &gt; 3 year prior study entry . 11 . Primary ocular melanoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>